CI-PAHT@EC2608A

LEOCH INT'L

STARGLORY HLDGS

INTELLIMARK W27

BEST FOOD HLDG

GAOYU FINANCE

EXTREME VISION

TIAN TU CAPITAL

HSC RESOURCES

EPI (HOLDINGS)

LAP KEI ENGRG

01833

512010

510660

513120

589720

516610

159929

IMED

Huatai Securities analyst maintained a Buy rating on Ping An Healthcare and Technology Company yesterday and set a price target of HK$15.90.Claim 30% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Ping An Healthcare and Technology Company has an analyst consensus of Moderate Buy, with a price target consensus of HK$16.67.

Tip Ranks

PA GOODDOCTOR

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

China Universal 800 Health Care ETF

AJM Ventures LLC

Huatai Securities Sticks to Its Buy Rating for Ping An Healthcare and Technology Company (PANHF)

Jefferies Reaffirms Their Hold Rating on Ping An Healthcare and Technology Company (PANHF)

businessinsider

Jefferies Reaffirms Their Hold Rating on Ping An Healthcare and Technology Company (PANHF)

UBS released a report, lowering the target price for PA GOODDOCTOR to 14.5 yuan, with a rating of "Neutral." The company's revenue last year grew by 13.7% year-on-year to 5.47 billion yuan, with a net profit of 378 million yuan, and a non-International Financial Reporting Standards net profit of 414 million yuan. The net profit margin and adjusted net profit margin increased to 6.9% and 7.6%, respectively. Revenue growth was mainly driven by an increase in the number of paying users and user spending, while the improvement in profit margins was attributed to business portfolio optimization and enhanced operational efficiency

AASTOCKS

UBS lowers PA GOODDOCTOR's target price to 14.5 yuan, rating "Neutral"

PA GOODDOCTOR's stock price rose today, opening up 4% to HKD 11.96, with a maximum increase of 10.8%. The latest quote is HKD 12.63, an increase of 9.83%. The company announced its 2025 annual results, with revenue of RMB 5.468 billion, a year-on-year increase of 13.7%; gross profit of RMB 1.772 billion, an increase of 16.3%; and net profit of RMB 380 million, an increase of 366.1%. Citigroup maintains a "Buy" rating with a target price of HKD 18

Tasty Money

PA GOODDOCTOR (1833) reported a net profit of 380 million yuan last year, an increase of 366.1% year-on-year

After years of wild growth and valuation water-squeezing in the internet healthcare industry, PA GOODDOCTOR is trying to tell a new profitability story to the capital markets

- Ping An Good Doctor has reported a significant shift towards profitability, with 2025 total revenue of 5.468 billion yuan, a 13.7% increase, and a net profit of 414 million yuan, up 161.3%.  
- This turnaround is largely due to its integration within the Ping An Group, which contributed 2.28 billion yuan, accounting for 41.7% of total revenue.  
- The report reflects a broader trend in the internet healthcare industry, where companies now seek to align closely with larger corporate entities rather than pursue independent platforms.

Wallstreetcn

Stronger After No Longer "Flying Solo"

Ping An Good Doctor Executive Director Zang Luoqi stated that last year AI contributed approximately 4.5% to the company's gross profit, directly contributing about 80 million RMB. The company invested nearly 70 million RMB in AI digital healthcare last year and will increase AI investment this year to promote AI upgrades and applications. The short-term goal is to improve gross profit and optimize the fee rate, with a net profit target at a higher than average industry level, and a medium to long-term expectation of achieving double-digit growth in net profit margin

PA GOODDOCTOR: Last year, AI contributed approximately 4.5% to gross profit, and this year will increase investment in AI

PA GOODDOCTOR's stock price rose over 9% today, opening at RMB 11.96 and reaching a high of RMB 12.74. The company's revenue last year was RMB 5.468 billion, a year-on-year increase of 13.7%; gross profit was RMB 1.772 billion, an increase of 16.3%; net profit was RMB 380 million, an increase of 366.1%. Earnings per share were RMB 0.18, with adjusted net profit of RMB 414 million, an increase of 161.3%. Citigroup set a target price of RMB 18, rating it as "Buy."

PA GOODDOCTOR rose over 9%, with last year's net profit of 380 million RMB soaring 3.66 times above expectations

Ping An Healthcare and Technology's Profit Soars 366% in 2025

marketscreener

Ping An Healthcare and Technology's Profit Soars 366% in 2025

Ping An Healthcare and Technology Company has published its audited annual results for the year ending December 31, 2025, meeting Hong Kong listing requirements. The report includes financial statements and governance details, reviewed by the audit committee. While specific financial figures are not disclosed, the report indicates operational continuity. The board, led by Michael Guo, approved the disclosure, emphasizing governance oversight. The current analyst rating for the stock (HK:1833) is a Hold with a price target of HK$14.50. The company focuses on digital healthcare services in China.

Ping An Healthcare and Technology Publishes 2025 Audited Annual Results

603939

603883

605266

002727

36Kr learned that recently, after Ping An Good Doctor reached deep cooperation with two major listed chain pharmacies, LBX and Yifeng, the "Ping An Circle" offline service network has achieved significant implementation in the southwest market: "Ping An Circle" successfully signed deep cooperation agreements with three regional chains, YIXINTANG, JZJ, and Guizhou Yishu

36Kr

Yifeng Pharmacy

YIXINTANG

The "Ping An Circle" has signed a deep cooperation agreement with YIXINTANG, JZJ, and Guizhou Yishu, three major regional chains

Bank of America Securities expects PA GOODDOCTOR's performance in 2025 to meet market expectations, with revenue growing by 14% to RMB 5.5 billion and net profit increasing by 72% to RMB 260 million. The firm has raised its revenue forecasts for 2025 and 2026, primarily due to a 37% growth in corporate business. It is expected that the net profit margin will expand by 1.6 percentage points to 4.8%. The rating is maintained at "underperform," with the target price raised from HKD 7 to HKD 8.3

According to Bank of America Securities, PA GOODDOCTOR's performance last year is expected to meet market expectations, maintaining a "underperform" rating

The chairman of Good Doctor Pharmaceutical proposed a special subsidy fund to promote AI in grassroots medical institutions during China's National People's Congress. The fund would offer purchase subsidies of 30-50% for AI systems, with rural areas potentially receiving up to 60%. This initiative aims to enhance AI application in community health services, which face funding challenges. Other NPC delegates also suggested pilot programs and increased policy support for AI in healthcare, emphasizing the need for a unified platform for medical data to aid AI development.

Yicai

Good Doctor Chair Proposes Special Fund to Promote AI in Basic Medical Institutions at Two Sessions

00241

Daiwa Capital Markets' research report points out that the mainland internet healthcare sector is entering a new stage, driven by innovations in AI from tech giants and support from national policies. Despite facing profitability challenges, leading companies are leveraging the AI ecosystem to achieve long-term growth. The firm is optimistic about ALI HEALTH and PA GOODDOCTOR, maintaining a "Buy" rating with target prices of 7.8 yuan and 20 yuan, respectively. It is expected that ALI HEALTH's revenue and net profit compound annual growth rates for the fiscal years 2026 to 2028 will be 13% and 24%; PA GOODDOCTOR's revenue and net profit compound annual growth rates for 2025 to 2027 will be 16% and 56%

ALI HEALTH

Daiwa Capital Markets: AI innovation and national policies drive the mainland internet healthcare sector, optimistic about ALI HEALTH and PA GOODDOCTOR

$XTALPI(02228.HK) Goldman Sachs launched the &#34;China AI Healthcare Index&#34; today, with Pharmaron as the top-weighted stock $ALI HEALTH(00241.HK)$JD HEALTH(06618.HK)$PA GOODDOCTOR(01833.HK)$YIDU TECH(02158.HK)$MircroPort Medbot-B(02252.HK)

CI-PAHT@EC2608A(27339.HK)

CI-PAHT@EC2608A Stock Performance Chart

Huatai Securities Sticks to Its Buy Rating for Ping An Healthcare and Technology Company (PANHF)

Jefferies Reaffirms Their Hold Rating on Ping An Healthcare and Technology Company (PANHF)

UBS lowers PA GOODDOCTOR's target price to 14.5 yuan, rating "Neutral"

PA GOODDOCTOR (1833) reported a net profit of 380 million yuan last year, an increase of 366.1% year-on-year

Stronger After No Longer "Flying Solo"